Prediction of Antiangiogenic Treatment Efficacy by Iron Oxide Enhanced Parametric Magnetic Resonance Imaging
Authors:
- Thorsten PersigehlTPThorsten Persigehl
- Lars MatuszewskiLMLars Matuszewski
- Torsten KesslerTorsten Kessler
- Alexander WallAWAlexander Wall
- Norbert MeierNMNorbert Meier
- Wolfgang EbertWEWolfgang Ebert
- Wolfgang E. BerdelWBWolfgang E. Berdel
- Walter HeindelWHWalter Heindel
- Rolf MestersRMRolf Mesters
- Christoph BremerCBChristoph Bremer
- 1 December 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 42 (12) , 791-796
Abstract
Tools for monitoring modern target-specific antiangiogenic and antivascular therapies are highly desirable because treatment strategies are time consuming, expensive, and yet sometimes ineffective. Therefore, the aim of this experimental study was to evaluate the predictive value of steady-state ultrasmall particles of iron oxide (USPIO; SH U 555 C)-enhanced magnetic resonance imaging (MRI) for early assessment of antivascular tumor-treatment effectiveness.Mice were inoculated with an HT-1080 fibrosarcoma xenograft and subjected to target-specific antivascular therapy using a selective thrombogenic vascular-targeting agent (truncated tissue factor fused to RGD peptide) or saline as control. Four to 8 hours after treatment, the USPIO-induced change in the transverse relaxation rate DeltaR2* was measured by MRI, and the vascular volume fraction (VVF) was calculated by calibrating DeltaR2* of the tumor by DeltaR2* of muscle tissue. Treatment response was defined by histologic grading of vascular thrombosis and tumor necrosis.After thrombogenic treatment, half of the HT-1080 xenograft-bearing animals showed only minor (=nonresponder) whereas the other half showed extensive tumor thrombosis (=responders). For responders, a significant decrease of DeltaR2* and VVF was observed compared with the control group (DeltaR2*: controls: 16 +/- 1 s-1 vs. responder: 4 +/- 2 s-1; P < 0.001) whereas DeltaR2* and VVF remained nearly unchanged for nonresponders (DeltaR2*: nonresponder 14 +/- 2 s-1). VVF and DeltaR2* values correlated inversely with the histologic grading of vascular thrombosis and tumor necrosis (VVF: r = -0.8; DeltaR2*: r = -0.71; P < 0.01).USPIO-enhanced MRI allows a noninvasive, early assessment of treatment efficacy of thrombogenic vascular-targeting agents.Keywords
This publication has 29 references indexed in Scilit:
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Assessment of Early Response to Tumor Necrosis Factor Alpha in a Colon Carcinoma ModelInvestigative Radiology, 2006
- Microbubble Contrast AgentsInvestigative Radiology, 2006
- Magnetic Resonance Macromolecular Agents for Monitoring Tumor Microvessels and Angiogenesis InhibitionInvestigative Radiology, 2006
- Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical OncologyJournal of Clinical Oncology, 2006
- Inhibition of Tumor Growth by RGD Peptide–Directed Delivery of Truncated Tissue Factor to the Tumor VasculatureClinical Cancer Research, 2005
- Angiogenesis Inhibitors: Current & Future DirectionsCurrent Pharmaceutical Design, 2004
- Steady-State Blood Volume Measurements in Experimental Tumors with Different Angiogenic Burdens—A Study in MiceRadiology, 2003
- MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status reportEuropean Journal of Radiology, 2000
- Antiangiogenesis for cancer therapyThe Lancet, 1997
- Assessing tumor angiogenesis using macromolecular MR imaging contrast mediaJournal of Magnetic Resonance Imaging, 1997